We are also eligible to receive up to $700 million in additional milestone payments related to our COVID-19 vaccine and ...

Novavax, Inc. ( NASDAQ: NVAX) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET ...

A collaboration with Sanofi offers flexibility and potential growth, allowing Novavax to focus on developing a COVID-19/influenza combination (CIC) and seasonal influenza vaccines. Despite ...

After an investigation, the agency concluded that a case of muscle weakness in one of Novavax’s trials was actually ALS and ...

3, KP.3.1.1 and LB.1. The company also recently entered into a licensing agreement worth over $1.2bn with Sanofi to ...

The Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its ...

Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...

The FDA agreed for Novavax to continue trials of its vaccine combo after addressing a serious adverse event that paused ...

As head of HHS, Kennedy would lead a sprawling federal department that encompasses more than 100 programs supporting medicine ...

Novavax Inc (NVAX) reports increased product sales and a strong cash position, while revising revenue guidance and navigating ...

influenza. "This merger helped the two companies gain leverage in the market, taking advantage of synergies to cut costs and increase development." On 6 May 2011, Sanofi-Aventis simplified its ...

Trump announced Thursday he'll nominate Robert F. Kennedy Jr. to be secretary of the Health and Human Services Department, ...